Dr. Michaela L. Tsai, MD
Hematology & Oncology (Hematology & Oncology Physician)
1221 Madison St, 2nd Fl
Seattle, WA 98104
Who else practices at this address →
King County includes primary care (5% of residents) and dental (4% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1995)
- Years since graduation
- 31
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 156
Licensed in Washington since 2021, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1995Medical school: Harvard Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD61182267 (first issued 2021; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Swedish Medical Center Seattle, WA
- Swedish Medical Center / Cherry Hill Seattle, WA
- Swedish Edmonds Hospital Edmonds, WA
- Olympic Medical Center Port Angeles, WA
- Swedish Issaquah Issaquah, WA
Medical groups
- Swedish Health Services (1,037 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 156
- Services billed
- 596
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 236 | 110 |
| Established patient office or other outpatient visit, 40-54 minutes | 71 | 39 |
| Established patient office or other outpatient visit, 20-29 minutes | 67 | 56 |
| New patient office or other outpatient visit, 60-74 minutes | 24 | 24 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Seattle, WA | 188 |
| Tamoxifen Citrate Other prescribers in Seattle, WA | 175 |
| Letrozole Other prescribers in Seattle, WA | 142 |
| Exemestane | 30 |
| Calquence (acalabrutinib maleate) | 25 |
| Gabapentin Other prescribers in Seattle, WA | 24 |
| Verzenio (abemaciclib) | 18 |
| Zarxio (filgrastim-sndz) | 14 |
| Acyclovir Other prescribers in Seattle, WA | 13 |
| Eliquis (apixaban) Other prescribers in Seattle, WA | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $4.13 in total to this clinician.
| Pfizer Inc. | $4.13 |
|---|
| Food and Beverage | $4.13 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 7 companies. The companies reported $253,554 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual…
AstraZeneca Pharmaceuticals LP - Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
AbbVie Inc. · Completed · NCT02947347 - A phase 1B2 openlabel multicenter dose escalation and dose expansion study to evaluate the safety tolerability pharmacokinetics pharmacodynamics and antitumor activity of PF07220060 in combination with PF07104091 plus…
Pfizer Inc. - CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - A phase 1 dose escalation and expansion study to evaluate safety tolerability pharmacokinetic pharmacodynamic and antitumor activity of PF07248144 in participants with advanced or metastatic solid tumors
Pfizer Inc. - Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
Eli Lilly and Company · Active, not recruiting · NCT03155997 - A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma
Acerta Pharma LLC - A Study of Samuraciclib and Elacestrant in Participants with Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer, Interventional
Stemline Therapeutics Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.